- You can view the full Sanofi Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
The stock has been on fire.
If one of the two were to successfully acquire the company, it would get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer.
Plus more from the biotechnology world on Wednesday, June 7.
The magnetic tape cartridges in the company's products will be under review.